PALVEN
An investigator-initiated Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer
Recruiting at: Royal Melbourne Hospital, Peter MacCallum Cancer Centre and Austin Hospital
Primary Investigator: Professor Geoff Lindeman
Clinical trial register: NCT03900884
Women with ER positive, BCL2 positive, and HER2 non-amplified metastatic breast cancer may be eligible for this study. For inclusion, prior lines of endocrine therapy or chemotherapy may be acceptable, however participants must not have previously been on venetoclax or palbociclib therapies. Participants must not receive any cancer treatment in the 21 days prior to commencing study treatment.
​
For more information contact transbcr@wehi.edu.au​
